We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Hutchison China MediTech
Impressive data means SANET-ep trial stopped earlyScancell
Vulpes investment brings £3.88m in new fundsBerGenBio
ASCO: more supportive data for bemcentinibMereo BioPharma
Encouraging interim BPS-804 data in OIHutchison China MediTech
Timing is right for a Hong Kong debutNexstim
Getting back on the front footScancell
SCIB2 to use new nanoparticle formulationMereo BioPharma
Focus shifts back to imminent dataMaxCyte
Dosing advances to second cohort in CARMA Phase IBonesupport
Building momentum